TRPX - セラピクス・バイオサイエンシズ (Therapix Biosciences Ltd.)

TRPXのニュース

   Therapix Biosciences raises $2.6M in private placement (NASDAQ:TRPX)  2020/06/29 13:34:50 Seeking Alpha
Therapix Biosciences (NASDAQ:TRPX) entered into definitive agreements for the issuance of an aggregate of 5.2M ADSs at a purchase price of $0.50/ADS, and w
   Therapix Biosciences Raises $2.6 Million in Private Placement  2020/06/29 13:10:00 PR Newswire
TEL-AVIV, Israel, June 29, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced that it has entered into definitive…
   Therapix Biosciences Closes A Joint Venture Transaction For its Sleep Indication  2020/05/19 12:30:00 PR Newswire
TEL AVIV, Israel, May 19, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company" or "Therapix"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today that it has closed a joint venture…
   Therapix Biosciences Appoints Prof. Ari Shamiss (M.D., M.P.A.) to the Company's Board of Directors  2020/05/07 22:04:00 PR Newswire
TEL AVIV, Israel, May 7, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announces today the appointment of Prof. Ari Shamiss (M.D., M.P.A.) to the…
   Therapix Biosciences Announces Appointment of New CEO  2020/04/22 20:30:00 PR Newswire
TEL AVIV, Israel, April 22, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today the appointment of Mr. Gilad Bar-Lev as CEO of the…
   Therapix Biosciences Closes A Joint Venture Transaction For its Sleep Indication  2020/05/19 12:30:00 PR Newswire
TEL AVIV, Israel, May 19, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company" or "Therapix"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today that it has closed a joint venture…
   Therapix Biosciences Appoints Prof. Ari Shamiss (M.D., M.P.A.) to the Company's Board of Directors  2020/05/07 22:04:00 PR Newswire
TEL AVIV, Israel, May 7, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announces today the appointment of Prof. Ari Shamiss (M.D., M.P.A.) to the…
   Therapix Biosciences Announces Appointment of New CEO  2020/04/22 20:30:00 PR Newswire
TEL AVIV, Israel, April 22, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today the appointment of Mr. Gilad Bar-Lev as CEO of the…
   Therapix Biosciences Ltd. Receives Nasdaq Notification Regarding Minimum Bid Requirements  2020/02/27 21:01:00 PR Newswire
TEL AVIV, Israel, Feb. 27, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today that on February 24, 2020, the Company received a written notice from…
   Nasdaq Hearings Panel Grants Therapix Biosciences Extension to Regain Compliance With Listing Requirements  2020/02/06 21:01:00 PR Newswire
TEL AVIV, Israel, Feb. 6, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today that on February 5, 2020, it received notice that the Nasdaq Hearings…
   Therapix Biosciences Ltd. Receives Nasdaq Notification Regarding Minimum Bid Requirements  2020/02/27 21:01:00 PR Newswire
TEL AVIV, Israel, Feb. 27, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today that on February 24, 2020, the Company received a written notice from…
   Nasdaq Hearings Panel Grants Therapix Biosciences Extension to Regain Compliance With Listing Requirements  2020/02/06 21:01:00 PR Newswire
TEL AVIV, Israel, Feb. 6, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today that on February 5, 2020, it received notice that the Nasdaq Hearings…
   Cannabis Stock Gainers And Losers From Dec. 18, 2019  2019/12/18 21:59:56 Benzinga Feeds
Gainers Columbia Care (OTC: CCHWF ) shares rose 1.38%, to close at $2.33. Fire & Flower Holdings (OTC: FFLWF ) shares increased by 2.49% to close at $0.69. GrowGeneration (NASDAQ: GRWG ) shares increased by 0.23% to close at $4.32 after announcing that it had acquired Oregon-Based GrowWorld . GW Pharmaceuticals (NASDAQ: GWPH ) shares rose 1.31%, to close at $107.47. Innovative Industrial (NYSE: IIPR ) shares increased by 0.78% to close at $74.00. Akerna (NASDAQ: KERN ) shares increased by 1.45% to close at $11.16 after announcing it would purchase Ample Organics in a $45 million liquidity and stock deal . Alcanna (OTC: LQSIF ) shares gained 1.35%, closing at $3.42. Planet 13 Holdings (OTC: PLNHF ) shares gained 6.67%, closing at $1.76. Trulieve Cannabis (OTC: TCNNF ) shares increased by 2.11% to close at $10.62. Therapix Biosciences (NASDAQ: TRPX ) shares gained 0.47%, closing at $1.10. Valens Groworks (OTC: VGWCF ) … Full story available on Benzinga.com
   The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win  2019/12/12 12:38:44 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 11) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aprea Therapeutics Inc (NASDAQ: APRE ) Aptose Biosciences Inc (NASDAQ: APTO ) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ) Arvinas Inc (NASDAQ: ARVN ) Audentes Therapeutics Inc (NASDAQ: BOLD ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) GlaxoSmithKline plc (NYSE: GSK ) Gossamer Bio Inc (NASDAQ: GOSS ) Immunomedics, Inc. (NASDAQ: IMMU ) Incyte Corporation (NASDAQ: INCY ) IVERIC bio Inc (NASDAQ: ISEE ) Kadmon Holdings Inc (NYSE: KDMN ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) Repro-Med Systems, Inc.
   Therapix Biosciences Announces Pricing of $1,250,000 Registered Direct Offering  2019/12/04 13:45:00 Benzinga Feeds
TEL AVIV, Israel , Dec. 4, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. (" Therapix " or the " Company ") (NASDAQ: TRPX ), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced that it has entered into definitive agreements with several accredited and institutional investors providing for the issuance of an aggregate of 1,000,000 American depositary shares (" ADSs ") at a purchase price of $1.25 per ADS in a registered direct offering. The offering is expected to result in gross proceeds to Therapix of $1,250,000 . Therapix intends to use the net proceeds from the offering for general corporate purposes. The closing of the sale of the securities is expected to take place on December 6, 2019 , subject to satisfaction of customary closing conditions. The ADSs described above were offered pursuant to a shelf registration statement on Form F-3 (File No. 333-225745), which was declared effective by the United States Securities and Exchange Commission (" SEC ") on July 20, 2018 .

calendar